Insider

Teva Pharmaceutical Industries Ltd

TEVA Health Care · 5 analyses · 11 expectations tracked

Teva Pharmaceutical Industries reported $4.4B in revenue (-1.9% YoY), compared with a +7.2% median across covered Health Care peers. Insider tracks 11 open management expectations for this company. 6 insider sales recorded.

Mentioned in recent filings: Ukraine Russia Tariffs

What changed

What changed

Teva повідомила про відставку головного медичного директора

Ерік Г'юз, виконавчий віцепрезидент та головний медичний директор Teva Pharmaceutical Industries, 17 листопада 2026 року повідомив про відставку. Він негайно залишає свою посаду заради пропозиції в іншій компанії, але допомагатиме з передачею справ упродовж наступних кількох місяців.

Company history

October 2026

Teva Pharmaceutical Industries Ltd. appointed a new member to its Board of Directors in October 2026.

  • On October 27, 2026, the Board of Directors elected Dr. David J. Brailer to serve as a member of the Board, effective November 3, 2026, until Teva's 2027 annual meeting of shareholders. Source
  • Dr. David J. Brailer will receive the same compensation as Teva’s other non-executive directors. Source

September 2026

Teva subsidiaries issued multiple series of senior notes guaranteed by the company.

  • TPFN II issued €1,000,000,000 of 4.250% Senior Notes due 2033, guaranteed by Teva. Source
  • TPFN III issued $500,000,000 of 5.500% Senior Notes due 2034 and $500,000,000 of 5.750% Senior Notes due 2037, guaranteed by Teva. Source
  • TPFN IV issued $500,000,000 of 5.250% Senior Notes due 2032, $500,000,000 of 5.250% Senior Notes due 2032, and $200,000,000 of 5.250% Senior Notes due 2032. Source
  • The notes were registered under a registration statement filed on 7 February 2025. Source

Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.

Key figures

From the 10-Q for the period ended September 30, 2026, filed November 3, 2026. SEC

LatestEarlierChange
Revenue quarter$4.4B$4.5B-1.9%
Operating income quarter$714M$882M-19.0%
Net income quarter$233M$433M-46.2%
Diluted EPS quarter$0.20$0.37-45.9%
Operating cash flow quarter$241M$369M-34.7%
Cash and cash equivalents balance$4.1B$3.6B+14.9%

Next results expected around February 2, 2027 (estimate: the quarter ending about December 30, 2026 plus the 34 days the last report took). The company announces the actual date.

As the company tagged them in its filing (SEC XBRL). Quarter and year figures are compared with the same period a year earlier, balances with the previous balance sheet. Download CSV

Revenue by quarter, $B

4.2Q4 '24*-0.7%3.9Q1 '2513.3%4.2Q2 '2510.9%4.5Q3 '2519.7%4.7Q4 '25*6.4%4Q1 '2616.4%4.1Q2 '26-5.6%4.4Q3 '2616.2%
Bottom row: operating margin (operating income divided by revenue). Q4 = fiscal year minus the three quarters reported on their own. Revenue as the company tagged it in its SEC filings (XBRL). Guidance is the company's own, not our forecast.

Sector peers

How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.

CompanyLatest revenueRevenue YoYOperating margin
Teva Pharmaceutical Industries Ltd TEVA$4.4B-1.9%16.2%
Unitedhealth Group Inc UNH$113B-0.4%5.8%
Mckesson Corp MCK$111B+7.6%1.4%
CVS Health Corp CVS$108B+5.4%3.3%
Cigna Group CI$73.7B+5.6%3.3%
Cardinal Health Inc CAH$67.5B+5.5%1.1%
Elevance Health, Inc. ELV$51.4B+1.4%2.5%

Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.

Expectations and reality

Open

  • The company targets peak sales potential of $1.5 billion–$2.0 billion for its LAI schizophrenia portfolio (UZEDY and WELTRUZA).

    Said November 3, 2026 · Source · Our article

    AI assessment, provisional no new evidence in later reports yet (as of November 18, 2026) · Later article

  • Free Cash Flow guidance for 2026 updated to $2.1 - $2.4 billion.

    Said November 3, 2026 · Period named: 2026 · Source · Our article

    Not yet checked against later reports.

  • Teva has a goal to achieve two times debt leverage.

    Said November 3, 2026 · Period named: end of 2027 · Source · Our article

    Not yet checked against later reports.

  • AUSTEDO revenue guidance for 2026 updated to $2,550 - $2,650 million.

    Said November 3, 2026 · Period named: 2026 · Source · Our article

    Not yet checked against later reports.

  • The company expects its annual non-GAAP tax rate for 2026 to be between 20%-23%.

    Said November 3, 2026 · Period named: 2026 · Source · Our article

    Not yet checked against later reports.

  • Operating Income guidance for 2026 updated to $3.8 - $3.9 billion.

    Said November 3, 2026 · Period named: 2026 · Source · Our article

    Not yet checked against later reports.

Show all (11)
  • AJOVY revenue guidance for 2026 updated to $930 - $960 million.

    Said November 3, 2026 · Period named: 2026 · Source · Our article

    Not yet checked against later reports.

  • Revenue guidance for 2026 updated to $16.7 - $17.0 billion.

    Said November 3, 2026 · Period named: 2026 · Source · Our article

    Not yet checked against later reports.

  • The company increased its 2026 revenue outlook for AUSTEDO to $2.55 billion–$2.65 billion.

    Said November 3, 2026 · Period named: 2026 · Source · Our article

    Not yet checked against later reports.

  • UZEDY revenue guidance for 2026 updated to $290 - $310 million.

    Said November 3, 2026 · Period named: 2026 · Source · Our article

    Not yet checked against later reports.

  • The company increased its 2026 revenue outlook for AJOVY to $930 million–$960 million.

    Said November 3, 2026 · Period named: 2026 · Source · Our article

    Not yet checked against later reports.

What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.

Governance events

Filings about how the company is run: auditor changes, restatements, leadership changes, late filings, delistings, Schedule 13D stakes and SEC comment letters, newest first.

DateEventFiling
October 29, 2026Director or officer departure or appointment (8-K item 5.02)8-K
September 14, 2026Removal of a security from listing (Form 25)25-NSE

As filed with the SEC, read by code. A comment letter is part of the SEC staff’s routine review and does not by itself mean a problem; item 5.02 covers appointments as well as departures; Form 25 may concern a bond or another class of securities.

Insider trades

DatePersonTradeSharesAvg. priceValueFiling
November 12, 2026Mark SabagSale notice filed44,710$44.14$1,973,544SEC
November 11, 2026Richard DaniellSale45,003$42.86$1,928,944SEC
November 11, 2026Daniell RichardPlanned sale20,003—$856,155SEC
November 10, 2026Richard D FrancisSale 10b5-1 plan notice filed250,000$42.24$10,559,175SEC
November 9, 2026Daniell RichardPlanned sale25,000—$1,072,789SEC
November 9, 2026Amir WeissSale17,289$43.04$744,049SEC
November 5, 2026Mark SabagSale46,000$41.93$1,928,729SEC
November 4, 2026Dov BergwerkSale notice filed26,260$41.72$1,095,567SEC

All insider trades →

Large funds (13F)

FundSharesValueChange in sharesQuarter
BlackRock63,419,932$2,511,429,311-0.7%Q3 2026
Norges Bank (Norway's sovereign fund)32,299,753$1,094,315,632—Q2 2026
Fidelity (FMR)25,784,696$1,021,073,928-14.8%Q3 2026
State Street19,309,106$764,640,598+2.0%Q3 2026
Wellington Management7,671,157$259,898,799+5.8%Q2 2026
Millennium Management1,465,716$58,042,354-55.1%Q3 2026
Bridgewater Associates982,873$38,921,771-25.9%Q3 2026
Citadel Advisors766,167$30,340,213+945.2%Q3 2026
D. E. Shaw & Co.205,840$8,151,264+13.9%Q3 2026
Two Sigma Investments193,287$7,654,165-16.4%Q3 2026
ARK Investment Management (Cathie Wood)68,295$2,735,355-0.5%Q3 2026
T. Rowe Price2,124,686$84,139+26.5%Q3 2026
Duquesne Family Office (Stanley Druckenmiller)624,999$21,175-73.7%Q2 2026

From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.